Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acyclovir + Chemoradiotherapy in EBV+ Nasopharyngeal Carcinoma
NCT03656965Phase 3Unknown
- Sponsor
- Kuwait Cancer Control Center
- Start
- May 2018
- Primary completion
- May 2021
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 3, randomised trial of aciclovir in nasopharyngeal carcinoma (NPC) (2 arms), sponsored by Kuwait Cancer Control Center. Primary endpoint: Number of participants with Eliminated EBV titre as assessed by quantitative PCR-DNA at 3 months. Status: unknown.
02
Drugs
aciclovir
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT03656965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03656965.